{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:23:25Z","timestamp":1774992205513,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.semarthrit.2003.09.005","type":"journal-article","created":{"date-parts":[[2004,4,9]],"date-time":"2004-04-09T09:21:57Z","timestamp":1081502517000},"page":"311-319","source":"Crossref","is-referenced-by-count":89,"title":["Differential efficacy of human recombinant interferon-\u03b12a on ocular and extraocular manifestations of beh\u00e7et disease: results of an open 4-center trial"],"prefix":"10.1016","volume":"33","author":[{"given":"Ina","family":"K\u00f6tter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Vonthein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Zierhut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja Katrin","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhan","family":"G\u00fcnaydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bodo","family":"Grimbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Blaschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Hartmut","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"St\u00fcbiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2003.09.005_BIB1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0021-5155(99)00029-5","article-title":"Epidemiological features and visual prognosis of Beh\u00e7et\u2019s disease","volume":"43","author":"Ando","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB2","first-page":"453","article-title":"Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Beh\u00e7et disease","volume":"38","author":"Stadler","year":"1987","journal-title":"Hautarzt"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB3","first-page":"440","article-title":"Adamantiades-Beh\u00e7et disease. Therapeutic administration of systemic recombinant interferon-alpha-2a","volume":"44","author":"Zouboulis","year":"1993","journal-title":"Hautarzt"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/art.1780360721","article-title":"Beneficial effects of interferon-alpha 2b in Beh\u00e7et\u2019s disease","volume":"36","author":"Durand","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB5","first-page":"1098","article-title":"Systemic interferon alpha 2b treatment in Behcet\u2019s syndrome","volume":"21","author":"Hamuryudan","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0190-9622(94)70226-8","article-title":"Interferon therapy for Beh\u00e7et\u2019s disease","volume":"31","author":"Alpsoy","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB7","first-page":"313","article-title":"Erosive arthritis and posterior uveitis in Beh\u00e7et\u2019s disease","volume":"14","author":"K\u00f6tter","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000246374","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et\u2019s disease","volume":"192","author":"Azizlerli","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","article-title":"Interferon alpha for ocular Beh\u00e7et\u2019s disease","volume":"75","author":"Pivetti-Pezzi","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB10","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/S0140-6736(97)10114-3","article-title":"Loss of vision and diarrhoea","volume":"350","author":"Grimbacher","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB11","first-page":"1938","article-title":"Interferon-alpha treatment of Beh\u00e7et\u2019s disease","volume":"25","author":"O\u2019Duffy","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/ard.60.1.83","article-title":"HHV8 associated Kaposi\u2019s sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Beh\u00e7et\u2019s disease and complete remission of both disorders with interferon alpha","volume":"60","author":"Kotter","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","article-title":"Treatment of ocular symptoms of Beh\u00e7et\u2019s disease with interferon alpha 2a","volume":"82","author":"K\u00f6tter","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-2001-19687","article-title":"Beh\u00e7et\u2019s disease","volume":"218","author":"St\u00fcbiger","year":"2001","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon-alpha2a for the treatment of Beh\u00e7et\u2019s Disease with sight-threatening posterior or panuveitis","volume":"87","author":"K\u00f6tter","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"8697","key":"10.1016\/j.semarthrit.2003.09.005_BIB16","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB17","series-title":"Uveitis Scoring System","author":"BenEzra","year":"1991"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0950-3579(05)80196-7","article-title":"Beh\u00e7et\u2019s disease","volume":"9","author":"Rigby","year":"1995","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB20","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2165\/00003495-199142050-00006","article-title":"Practical treatment recommendations for pharmacotherapy of Beh\u00e7et\u2019s syndrome","volume":"42","author":"Yazici","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-4615-4857-7_19","article-title":"Beh\u00e7et\u2019s syndrome. The Cerrahpasa experience. Members of the Beh\u00e7et\u2019s Syndrome Research Centre","volume":"455","author":"Yazici","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB24","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/art.1780391216","article-title":"The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Beh\u00e7et\u2019s disease. A randomized clinical trial","volume":"39","author":"Calguneri","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(99)05131-4","article-title":"Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Beh\u00e7et\u2019s disease","volume":"355","author":"Demiroglu","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0753-3322(01)00154-8","article-title":"Thalidomide in Beh\u00e7et\u2019s disease","volume":"56","author":"Shek","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780400425","article-title":"Azathioprine in Beh\u00e7et\u2019s syndrome","volume":"40","author":"Hamuryudan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB29","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/art.1780290420","article-title":"Cyclosporin A is effective, but not safe, in the management of Beh\u00e7et\u2019s disease","volume":"29","author":"Wechsler","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0161-6420(83)80014-1","article-title":"Chlorambucil in Beh\u00e7et\u2019s disease. A reappraisal","volume":"90","author":"Tabbara","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1076\/ocii.9.4.219.3957","article-title":"Short-term chlorambucil for refractory uveitis in Beh\u00e7et\u2019s disease","volume":"9","author":"Mudun","year":"2001","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB33","first-page":"404","article-title":"Cyclophosphamide in the treatment of the ocular manifestations of Beh\u00e7et\u2019s disease","volume":"11","author":"Davatchi","year":"1984","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB34","first-page":"438","article-title":"Bolus of cyclophosphamide and methylprednisolone in uveitis in Beh\u00e7et\u2019s disease. Preliminary results with the use of new criteria of evaluation","volume":"143","author":"Hamza","year":"1992","journal-title":"Ann Med Interne (Paris)"},{"issue":"3 suppl 4","key":"10.1016\/j.semarthrit.2003.09.005_BIB35","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant Proc"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB36","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood.V65.6.1364.bloodjournal6561364","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndrome","volume":"65","author":"Michels","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","article-title":"Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy","volume":"106","author":"Kotake","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","article-title":"Central nervous system symptoms in a population of Beh\u00e7et\u2019s disease patients with refractory uveitis treated with cyclosporine A","volume":"29","author":"Kato","year":"2001","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB39","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/gast.2001.22556","article-title":"Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Beh\u00e7et\u2019s disease","volume":"120","author":"Hassard","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB40","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","article-title":"Effect of infliximab on threatening panuveitis in Beh\u00e7et\u2019s disease","volume":"358","author":"Munoz-Fernandez","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB42","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","article-title":"Treatment of intestinal Beh\u00e7et\u2019s syndrome with chimeric tumour necrosis factor alpha antibody","volume":"49","author":"Travis","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB43","first-page":"483","article-title":"Immunopathogenesis of Beh\u00e7et\u2019s disease","volume":"150","author":"Lehner","year":"1999","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB44","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","article-title":"Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon alfa","volume":"134","author":"Zouboulis","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB46","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0140-6736(00)02811-7","article-title":"Retraction","volume":"356","author":"Horton","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jmv.1890340212","article-title":"Autoantibodies during alpha-interferon therapy for chronic hepatitis B","volume":"34","author":"Fattovich","year":"1991","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.semarthrit.2003.09.005_BIB48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0090-1229(92)90250-R","article-title":"Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders","volume":"65","author":"Wandl","year":"1992","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB49","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2265.1996.751768.x","article-title":"Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy","volume":"44","author":"Marazuela","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0753-3322(99)80095-X","article-title":"Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis","volume":"53","author":"Dumoulin","year":"1999","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000057631","article-title":"Immune-mediated complications during interferon therapy in hematological patients","volume":"107","author":"Raanani","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB52","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/096120339700600603","article-title":"The concurrence of lupus and fibromyalgia","volume":"6","author":"Bennett","year":"1997","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB53","first-page":"324","article-title":"The treatment of hepatitis B and C with interferon-alpha can induce or aggravate psoriasis","volume":"19","author":"Cervoni","year":"1995","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/pmj.76.896.365","article-title":"Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C","volume":"76","author":"Taylor","year":"2000","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB55","first-page":"309","article-title":"Retinal complications during interferon therapy for chronic hepatitis C","volume":"91","author":"Kawano","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB56","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.1999.59","article-title":"Ocular complications with high-dose interferon alpha in chronic active hepatitis","volume":"13","author":"Kadayifcilar","year":"1999","journal-title":"Eye"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB57","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1600-0676.2001.021003192.x","article-title":"Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C","volume":"21","author":"Saito","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB58","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0002-9394(01)00836-4","article-title":"Retinopathy associated with high-dose interferon alfa-2b therapy","volume":"131","author":"Hejny","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.semarthrit.2003.09.005_BIB59","first-page":"79","article-title":"Severe necroziting vasculitis in a patient with hepatitis C virus infection treated by interferon","volume":"14","author":"Pateron","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB60","first-page":"1183","article-title":"Beh\u00e7et\u2019s disease induced by interferon therapy for chronic myelogenous leukemia","volume":"22","author":"Segawa","year":"1995","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2003.09.005_BIB61","first-page":"45","article-title":"Beh\u00e7et\u2019s disease in patients with chronic myelogenous leukemia","volume":"74","author":"Budak-Alpdogan","year":"1997","journal-title":"Ann Hematol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB62","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/37.11.1148","article-title":"Skin hyperreactivity of Beh\u00e7et\u2019s patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders","volume":"37","author":"Budak-Alpdogan","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB63","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0167-5699(96)10027-X","article-title":"The neglected role of type I interferon in the T-cell response","volume":"17","author":"Belardelli","year":"1996","journal-title":"Immunol Today"},{"issue":"5 suppl 24","key":"10.1016\/j.semarthrit.2003.09.005_BIB64","first-page":"S6","article-title":"Beh\u00e7et\u2019s disease","volume":"19","author":"G\u00fcl","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB65","first-page":"2466","article-title":"Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection","volume":"28","author":"Naarendorp","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2003.09.005_BIB66","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00005792-199509000-00002","article-title":"Polyarteritis nodosa18 related to hepatitis B virus. A prospective study with long-term observation of 41 patients","volume":"74","author":"Guillevin","year":"1995","journal-title":"Medicine (Baltimore)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017203001628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017203001628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T22:55:54Z","timestamp":1585695354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017203001628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0049017203001628"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2003.09.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}